Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on Precision BioSciences (DTIL – Research Report). The associated price target remains the same with $30.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Soumit Roy’s rating is based on the promising potential of Precision BioSciences’ in vivo gene editing platform, particularly in addressing chronic hepatitis B (HBV) and Duchenne muscular dystrophy (DMD). The company’s PBGENE-DMD program, which is part of their ARCUS gene editing platform, shows significant promise as a potential best-in-class treatment for DMD, with plans to complete IND/CTA-enabling studies by 2025 and present initial clinical data in 2026.
Additionally, the PBGENE-HBV program is progressing in its Phase 1 ELIMINATE-B trial, with early safety data looking favorable. The potential for PBGENE-HBV to offer a functional cure for HBV patients adds to the stock’s attractiveness. Precision BioSciences’ strategic focus on these large, underserved markets, combined with positive preclinical data, supports the Buy rating, as the company is well-positioned to capture a significant share of the market.
According to TipRanks, Roy is an analyst with an average return of -26.2% and a 17.84% success rate. Roy covers the Healthcare sector, focusing on stocks such as Precision BioSciences, Enliven Therapeutics, and Nuvation Bio.